Herantis Pharma Partners with Indivi for HER-096 Phase 2 Trial in Parkinson’s Disease

Herantis Pharma has announced a collaboration with Indivi to integrate Indivi’s digital biomarker platform into its upcoming Phase 2 trial for HER-096, a drug candidate aimed at modifying the progression of Parkinson’s disease. This partnership aims to use digital biomarkers to detect early treatment effects more sensitively than traditional assessments, enhancing the evaluation of HER-096’s therapeutic potential.